Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Unilever will not raise rejected 50 billion pound bid for GSK consumer arm

Published 01/19/2022, 11:44 AM
Updated 01/20/2022, 06:06 AM
© Reuters. FILE PHOTO: The logo of Unilever in Rotterdam, Netherlands August 21, 2018. REUTERS/Piroschka van de Wouw

© Reuters. FILE PHOTO: The logo of Unilever in Rotterdam, Netherlands August 21, 2018. REUTERS/Piroschka van de Wouw

(Reuters) - Unilever (NYSE:UL) PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline (NYSE:GSK)'s consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK previously rejected.

U.S.-listed shares of Unilever rose 10.1% on the news, while GSK's fell 2.8%. The two stocks also trade on the FTSE, where the day's trading had closed.

GSK has rejected three bids from Unilever for its consumer arm, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller, saying the bids "fundamentally undervalued" the business and its prospects.

It has said it would stick to its plan to separately list the business in mid-2022 and issued improved financial assumptions for the unit.

Unilever said in a statement it had noted these but "determined that it does not change our view on fundamental value. Accordingly, we will not increase our offer above £50 bln".

A spokesperson for GSK responded that the group was strongly focused on maximising shareholder value and very confident in the future of the consumer healthcare business in which Pfizer (NYSE:PFE) has a 32% stake.

"The Consumer Healthcare business has an exceptional portfolio and offers existing and prospective shareholders a highly attractive financial profile supporting investment and future returns," they added.

In a statement rebuffing Unilever's overtures last weekend, GSK said the bid failed to capture the unit's potential, releasing new forecasts that projected annual organic sales growth of 4%-6% for the business, which made sales of 9.6 billion pounds last year, over the medium term.

This estimate was above its prior forecast of seeking to beat the consumer health market's growth of about 4%.

The British drug maker said it intends to further share details of its strategy for the consumer brands unit at an investor day on 28 February.

The event would follow its fourth-quarter results on 9 February where it might also throw some light on its thinking.

Unilever's decision not to raise its bid comes after analysts and investors widely panned its offer, sending shares in the maker of Dove soap down 8% on Monday, on worries about the financial implications for the company.

A source familiar with Pfizer's strategy told Reuters earlier this week that GSK and Pfizer would open negotiations with Unilever's boss Alan Jope if the consumer goods giant was ready to improve its bid to more than 60 billion pounds.

© Reuters. FILE PHOTO: The logo of Unilever in Rotterdam, Netherlands August 21, 2018. REUTERS/Piroschka van de Wouw

(Corrects JAN 19 story to make clear Pfizer has stake in consumer healthcare business, paragraph 6)

($1 = 0.7337 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.